216 related articles for article (PubMed ID: 10027001)
41. Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the pancreas.
Hilgers W; Groot Koerkamp B; Geradts J; Tang DJ; Yeo CJ; Hruban RH; Kern SE
Genes Chromosomes Cancer; 2000 Mar; 27(3):239-43. PubMed ID: 10679912
[TBL] [Abstract][Full Text] [Related]
42. Common fragile sites, extremely large genes, neural development and cancer.
Smith DI; Zhu Y; McAvoy S; Kuhn R
Cancer Lett; 2006 Jan; 232(1):48-57. PubMed ID: 16221525
[TBL] [Abstract][Full Text] [Related]
43. Replacement of Fhit in cancer cells suppresses tumorigenicity.
Siprashvili Z; Sozzi G; Barnes LD; McCue P; Robinson AK; Eryomin V; Sard L; Tagliabue E; Greco A; Fusetti L; Schwartz G; Pierotti MA; Croce CM; Huebner K
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13771-6. PubMed ID: 9391102
[TBL] [Abstract][Full Text] [Related]
44. A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention.
Zanesi N; Pekarsky Y; Croce CM
Mutat Res; 2005 Dec; 591(1-2):103-9. PubMed ID: 16085127
[TBL] [Abstract][Full Text] [Related]
45. Common fragile sites and cancer (review).
Smith DI; Huang H; Wang L
Int J Oncol; 1998 Jan; 12(1):187-96. PubMed ID: 9454904
[TBL] [Abstract][Full Text] [Related]
46. Evidence that instability within the FRA3B region extends four megabases.
Becker NA; Thorland EC; Denison SR; Phillips LA; Smith DI
Oncogene; 2002 Dec; 21(57):8713-22. PubMed ID: 12483524
[TBL] [Abstract][Full Text] [Related]
47. Common chromosomal fragile sites and cancer: focus on FRA16D.
O'Keefe LV; Richards RI
Cancer Lett; 2006 Jan; 232(1):37-47. PubMed ID: 16242840
[TBL] [Abstract][Full Text] [Related]
48. FHIT as tumor suppressor: mechanisms and therapeutic opportunities.
Pekarsky Y; Palamarchuk A; Huebner K; Croce CM
Cancer Biol Ther; 2002; 1(3):232-6. PubMed ID: 12432269
[TBL] [Abstract][Full Text] [Related]
49. Components of DNA damage checkpoint pathway regulate UV exposure-dependent alterations of gene expression of FHIT and WWOX at chromosome fragile sites.
Ishii H; Mimori K; Inageta T; Murakumo Y; Vecchione A; Mori M; Furukawa Y
Mol Cancer Res; 2005 Mar; 3(3):130-8. PubMed ID: 15798093
[TBL] [Abstract][Full Text] [Related]
50. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors.
Shridhar R; Shridhar V; Wang X; Paradee W; Dugan M; Sarkar F; Wilke C; Glover TW; Vaitkevicius VK; Smith DI
Cancer Res; 1996 Oct; 56(19):4347-50. PubMed ID: 8813121
[TBL] [Abstract][Full Text] [Related]
51. The epicenter of chromosomal fragility of Fra14A2, the mouse ortholog of human FRA3B common fragile site, is largely attached to the nuclear matrix in lymphocytes but not in other cell types that do not express such a fragility.
Guadarrama-Ponce R; Aranda-Anzaldo A
J Cell Biochem; 2020 Mar; 121(3):2209-2224. PubMed ID: 31646677
[TBL] [Abstract][Full Text] [Related]
52. The Fragile Histidine Triad gene and breast cancer.
Yang Q; Yoshimura G; Sakurai T; Kakudo K
Med Sci Monit; 2002 Jul; 8(7):RA140-4. PubMed ID: 12118213
[TBL] [Abstract][Full Text] [Related]
53. Chromosome arm 8p and cancer: a fragile hypothesis.
Birnbaum D; Adélaïde J; Popovici C; Charafe-Jauffret E; Mozziconacci MJ; Chaffanet M
Lancet Oncol; 2003 Oct; 4(10):639-42. PubMed ID: 14554243
[TBL] [Abstract][Full Text] [Related]
54. Potential cancer therapy with the fragile histidine triad gene: review of the preclinical studies.
Ishii H; Dumon KR; Vecchione A; Fong LY; Baffa R; Huebner K; Croce CM
JAMA; 2001 Nov; 286(19):2441-9. PubMed ID: 11712940
[TBL] [Abstract][Full Text] [Related]
55. Association of allelic loss at the FHIT locus and p53 alterations with tumour kinetics and chromosomal instability in non-small cell lung carcinomas (NSCLCs).
Garinis GA; Gorgoulis VG; Mariatos G; Zacharatos P; Kotsinas A; Liloglou T; Foukas P; Kanavaros P; Kastrinakis NG; Vassilakopoulos T; Vogiatzi T; Field JK; Kittas C
J Pathol; 2001 Jan; 193(1):55-65. PubMed ID: 11169516
[TBL] [Abstract][Full Text] [Related]
56. Anomalous transcripts and allelic deletions of the FHIT gene in human esophageal cancer.
Menin C; Santacatterina M; Zambon A; Montagna M; Parenti A; Ruol A; D'Andrea E
Cancer Genet Cytogenet; 2000 May; 119(1):56-61. PubMed ID: 10812172
[TBL] [Abstract][Full Text] [Related]
57. Alterations of the FHIT gene in human hepatocellular carcinoma.
Yuan BZ; Keck-Waggoner C; Zimonjic DB; Thorgeirsson SS; Popescu NC
Cancer Res; 2000 Feb; 60(4):1049-53. PubMed ID: 10706123
[TBL] [Abstract][Full Text] [Related]
58. How many tumor suppressor genes are involved in human lung carcinogenesis?
Kohno T; Yokota J
Carcinogenesis; 1999 Aug; 20(8):1403-10. PubMed ID: 10426784
[TBL] [Abstract][Full Text] [Related]
59. Contig array CGH at 3p14.2 points to the FRA3B/FHIT common fragile region as the target gene in diffuse large B-cell lymphoma.
Kameoka Y; Tagawa H; Tsuzuki S; Karnan S; Ota A; Suguro M; Suzuki R; Yamaguchi M; Morishima Y; Nakamura S; Seto M
Oncogene; 2004 Dec; 23(56):9148-54. PubMed ID: 15480422
[TBL] [Abstract][Full Text] [Related]
60. Loss of FHIT expression in cervical carcinoma cell lines and primary tumors.
Greenspan DL; Connolly DC; Wu R; Lei RY; Vogelstein JT; Kim YT; Mok JE; Muñoz N; Bosch FX; Shah K; Cho KR
Cancer Res; 1997 Nov; 57(21):4692-8. PubMed ID: 9354423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
